GlassScriptPhysician profile
Zain I Memon
NPI 1679004154
$2,322.77
in general payments reported to CMS, 2019-2025
27 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $114 · 2021: $453 · 2022: $372 · 2023: $329 · 2024: $409 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $310.44 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $247.45 | 2021-2023 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $187.02 | 2024-2025 | |
| Viiv Healthcare Company | $168.04 | 2025 | Apretude |
| Qol Medical, LLC | $142.18 | 2020-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $128.34 | 2020-2024 | Gardasil 9, Gardasil |
| Janssen Biotech, INC. | $102.37 | 2022-2023 | Simponi Aria, Remicade, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.63 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $93.07 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $92.11 | 2020-2021 | |
| Exact Sciences Corporation | $91.70 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $89.11 | 2023-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $74.23 | 2024-2025 | |
| Abbvie INC. | $66.47 | 2021-2022 | |
| Redhill Biopharma INC. | $62.64 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $55.13 | 2024 | Entyvio |
| Kowa Pharmaceuticals America, INC. | $49.98 | 2025 | Zoryve |
| Intra-Sana Laboratories | $46.73 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Daiichi Sankyo INC. | $44.18 | 2022-2024 | Injectafer |
| Alfasigma USA, INC. | $34.46 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $31.05 | 2023-2024 | Voquezna |
| Abbott Laboratories | $26.02 | 2025 | Id Now Instrument |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.04 | 2020 | |
| Shield Therapeutics INC | $16.71 | 2024 | |
| Horizon Therapeutics Plc | $13.37 | 2021 | |
| Linus Health, INC. | $12.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zain Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.